Fortress Biotech, Inc. Q3 2026 Earnings Call Summary
Fortress Biotech: 3 Key Takeaways for Long-Term Investors
Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript
Fortress Biotech: Q3 Earnings Snapshot
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech Q3 EPS $(0.23) Misses $(0.15) Estimate, Sales $19.159M Miss $21.575M Estimate
Fortress Biotech, Inc. (FBIO) Q3 2026 Earnings Call Transcript
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.